Mogrify Ltd

Mogrify® is deploying its proprietary suite of cellular reprogramming technologies, MOGRIFY® and epiMOGRIFY, to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology and metabolic and other areas of degenerative disease.

Stay up to date with Mogrify Ltd

Login or create a free user account to follow this company and see updates on your dashboard.

Create account